Incorporate Patient Participation – Design Trials to Better Satisfy Patient Centric Outcomes Prior to Product Launch Presentation by Inspire Research Director Dave Taylor at Evidence for Value-Based Programs conference August 12, 2015

1. Patient Advocacy Panel:
Incorporate Patient Participation – Design Trials to Better
Satisfy Patient Centric Outcomes Prior to Product Launch
Evidence for Value-Based Programs
August 12, 2015

2. 2
► Inspire Background and Panelist Introductions
► Inspire Research Insights
• Clinical Trial Design Considerations
• Case Study: One More Lung Biopsy
► Structured, Expert Guidance
► Q & A
Agenda
5 minutes
5 minutes
10 minutes
20 minutes

3. Inspire Background and Panelist
Introductions

4. 4
Inspire Background
Social network for
PTs and CGs:
• ~648,000 members
• 200+ communities
• ~110 advocacy org.
partners
‘Born’ in 2005
Live in 2006
Member growth
through:
• Organic search
• Advocacy groups
• Miscellaneous
Goal was to connect
patients & caregivers
with one another
AND connect them
directly with pharma
(clinical trials)

5. 5
Panelist Introductions
Linnea Duff
Advanced Lung Cancer
Survivor
Advocate & Blogger
twitter.com/1111linno
outlivinglungcancer.com
Kari Luther Rosbeck
President and CEO
Tuberous Sclerosis
Alliance
>2,800 members in TS
Alliance Support
Community
Melanie Vogel
Mother and ‘caregiver’ to
daughter, Riley with TSC
Riley has participated in
clinical trials since Dx at
17 months old
Founder of Rock 4 Riley
(rock4riley.org)

6. Inspire Research Insights

7. 7
Clinical Trial Design Considerations
A while back, we were asked by a pharma partner to assess patient
willingness to participate in one of two clinical trial designs for IBD,
each of which had unique testing requirements
- Trial Design #1:
6-month trial in which
patient would have to
collect anywhere from 2
to 6+ stool samples
during that time
- Trial Design #2:
6-month trial in which
patient would have to
have 2 endoscopies
performed (one at the
start and one at the end
of the trial)
37%
54%
Overall, those who were
‘sicker’ (not in remission at
time of study, have had
more flares in past year)
were:
1) More willing to
participate, and
2) More willing to ‘do
more’ for the study
VALUE

8. 8
Case Study: One More Lung Biopsy
In some recent work we’ve done in
NSCLC, our pharma partner wanted to
know if patients would be willing to
undergo another lung biopsy if a new
genetic/biomarker test became available
that could inform additional treatment
options
Despite several having complications
with their previous biopsies (e.g.,
collapsed lung, infection, etc.), most
would consider the test
VALUE
At the Patient Adherence and Access
Summit in June, we took a close look at
the word “adherence”
“Adherence” and “compliance” represent
authoritative concepts, subliminally
elevating the HCP over their patients
We recognized the need for more
patient-centric concepts such as
“ownership” and “engagement”
In this session, we need to evaluate the
word “value” which has been used in the
context of pharma and providers
Deliver patients and their loved ones
their ‘WIIFM’ à “hope”, “outcomes”
“quality of life”

9. Expert Guidance

10. 10
Overcoming Obstacles Before & During
Clinical Trials
“If you show up regularly,
you adhere”
ASCO paying HCPs $350/
patient for those who stay
compliant with protocol
Food for thought:
- Setting expectations going into a
clinical trial
- What keeps patients coming back
for the trial
- What issues might a patient have
with:
- Trial center accessibility
- Finances (travel costs, etc.)
- Check-ins and evaluations
- Overall satisfaction
- Treatment satisfaction
- Quality of life
- What improvements can be made
to make clinical trial participation
more manageable

11. 11
True Patient-Centric Design: Early and Often
Food for thought:
- How can patients aid with the development of patient-reported
outcome tools and measurements?
- What should be the role patients play in helping to develop these
surveys/questionnaires?
In one of yesterday’s sessions, there was a graphic which showed
“Patient-centered endpoints” listed under Phase III of the new product
development cycle
- When should patients be involved in this process?

12. Q & A